董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Uri Geiger | 男 | Director and Chairman of the Board | 57 | 7.27万美元 | 未持股 | 2025-12-10 |
| Samuel Rubinstein | 男 | Independent Director | 86 | 5.99万美元 | 未持股 | 2025-12-10 |
| Irit Yaniv | 女 | Independent Director | 61 | 5.28万美元 | 未持股 | 2025-12-10 |
| Christina L. Allgeier | 女 | Independent Director | 53 | 1.56万美元 | 未持股 | 2025-12-10 |
| Dolev Rafaeli | 男 | Director,President,Chief Executive Officer and Vice-Chairman of the Board | 61 | 60.14万美元 | 未持股 | 2025-12-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shmuel Gov | 男 | Chief Operating Officer | 65 | 47.07万美元 | 未持股 | 2025-12-10 |
| John Gillings | -- | Chief Accounting Officer | 51 | 14.37万美元 | 未持股 | 2025-12-10 |
| Dolev Rafaeli | 男 | Director,President,Chief Executive Officer and Vice-Chairman of the Board | 61 | 60.14万美元 | 未持股 | 2025-12-10 |
董事简历
中英对照 | 中文 | 英文- Uri Geiger
-
Uri Geiger，2014年1月以来，一直担任本公司董事。他现为Accelmed的管理合伙人，这是他在2009年参与创办的私募股权投资公司，专注于医疗器械公司的投资。此前，2006年5月至2008年12月，他是医疗技术公司Exalenz Bioscience Ltd的首席执行官。此前，他曾参与创办光学组件开发商GalayOr Networks，并在2001-2003年间担任首席执行官。他从2000年起，成为Dragon Variation Fund的创始合伙人，这是以色列首批对冲基金之一。1999年回到以色列之前，他在华尔街获得了资本市场方面的丰富知识和经验。他曾是Tel Aviv University’s Recanati School of Business的兼职教授，讲授私募股权和风投课程，出版了《Startup Companies and Venture Capital》、《From Concept to Wall Street》两本书。他在New York’s Columbia University Center for Law & Economics获得全球股票市场专业的博士学位。他还曾是以色列空军的少校。
Uri Geiger,is Strata Skin Sciences, Inc. Chairman of the Board. Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. He currently serves as Strata's Chairman of the Board of Directors. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York's Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies. Dr. Geiger served as the Chairman of the Board of Directors of Cogentix Medical from November 2016 until its sale in April 2018 and he is currently on the board of a number of public and private medical device companies. Dr. Geiger has served on the board of directors of NeuroPace, Inc., a publicly traded medical device company focused on epilepsy, since January 2023 and Minerva Surgical, Inc., a publicly traded medical device company focused on uterine healthcare, since February 2023. - Uri Geiger，2014年1月以来，一直担任本公司董事。他现为Accelmed的管理合伙人，这是他在2009年参与创办的私募股权投资公司，专注于医疗器械公司的投资。此前，2006年5月至2008年12月，他是医疗技术公司Exalenz Bioscience Ltd的首席执行官。此前，他曾参与创办光学组件开发商GalayOr Networks，并在2001-2003年间担任首席执行官。他从2000年起，成为Dragon Variation Fund的创始合伙人，这是以色列首批对冲基金之一。1999年回到以色列之前，他在华尔街获得了资本市场方面的丰富知识和经验。他曾是Tel Aviv University’s Recanati School of Business的兼职教授，讲授私募股权和风投课程，出版了《Startup Companies and Venture Capital》、《From Concept to Wall Street》两本书。他在New York’s Columbia University Center for Law & Economics获得全球股票市场专业的博士学位。他还曾是以色列空军的少校。
- Uri Geiger,is Strata Skin Sciences, Inc. Chairman of the Board. Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. He currently serves as Strata's Chairman of the Board of Directors. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York's Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies. Dr. Geiger served as the Chairman of the Board of Directors of Cogentix Medical from November 2016 until its sale in April 2018 and he is currently on the board of a number of public and private medical device companies. Dr. Geiger has served on the board of directors of NeuroPace, Inc., a publicly traded medical device company focused on epilepsy, since January 2023 and Minerva Surgical, Inc., a publicly traded medical device company focused on uterine healthcare, since February 2023.
- Samuel Rubinstein
-
Samuel Rubinstein自2018年5月29日起成为公司董事，并在审计委员会以及薪酬/提名和治理委员会任职。Rubinstein先生在Taro Pharmaceuticals Industries担任了20多年的首席执行官兼总经理，这是一家纳斯达克上市的皮肤病公司。在他的管理下，Taro成长为一家跨国公司，在全球拥有超过1000名员工，营业额接近4.5亿美元。2003年，鲁宾斯坦先生获得杰出工业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际营销课程。Rubinstein先生担任Clal Biotechnology Industries，Exalenz，Medison Biotech，Trima Pharma，Kamada的董事会成员，并担任Marcum和Sol-Gel Pharma的顾问。Milky还是特拉维夫Sourasky Medical Center附近Medical Research Fund和the National Authority for Yiddish Culture董事。
Samuel Rubinstein has served as a member of the Board since May 2018. Mr. Rubinstein has many years of experience in the pharmaceutical and medical device fields, include having served for over 20 years as the Chief Executive Officer and General Manager of Taro Pharmaceuticals Indtries, overseeing its successful acquisition by SUN Pharma. In 2003, Mr. Rubinstein received the Exceptional Indtrialist award. During these years he also finished an International Marketing Cse at the Wharton School of the University of Pennsylvania. Mr. Rubinstein serves as a board member on the boards of Mediwound Ltd., Medison Biotech, Trima Pharma (where he serves as chairman), and KSDG. He previoly served on the boards of Exalenz (acquired by VIVO), Kamada (KMDA), and Clal Biotechnology Indtries (CBI), and is a consultant to Sol Gel Pharma. Mr. Rubinstein is also a director at the Medical Research Fund near The Tel Aviv Sasky Medical Center and The National Authority for Yiddish Culture. - Samuel Rubinstein自2018年5月29日起成为公司董事，并在审计委员会以及薪酬/提名和治理委员会任职。Rubinstein先生在Taro Pharmaceuticals Industries担任了20多年的首席执行官兼总经理，这是一家纳斯达克上市的皮肤病公司。在他的管理下，Taro成长为一家跨国公司，在全球拥有超过1000名员工，营业额接近4.5亿美元。2003年，鲁宾斯坦先生获得杰出工业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际营销课程。Rubinstein先生担任Clal Biotechnology Industries，Exalenz，Medison Biotech，Trima Pharma，Kamada的董事会成员，并担任Marcum和Sol-Gel Pharma的顾问。Milky还是特拉维夫Sourasky Medical Center附近Medical Research Fund和the National Authority for Yiddish Culture董事。
- Samuel Rubinstein has served as a member of the Board since May 2018. Mr. Rubinstein has many years of experience in the pharmaceutical and medical device fields, include having served for over 20 years as the Chief Executive Officer and General Manager of Taro Pharmaceuticals Indtries, overseeing its successful acquisition by SUN Pharma. In 2003, Mr. Rubinstein received the Exceptional Indtrialist award. During these years he also finished an International Marketing Cse at the Wharton School of the University of Pennsylvania. Mr. Rubinstein serves as a board member on the boards of Mediwound Ltd., Medison Biotech, Trima Pharma (where he serves as chairman), and KSDG. He previoly served on the boards of Exalenz (acquired by VIVO), Kamada (KMDA), and Clal Biotechnology Indtries (CBI), and is a consultant to Sol Gel Pharma. Mr. Rubinstein is also a director at the Medical Research Fund near The Tel Aviv Sasky Medical Center and The National Authority for Yiddish Culture.
- Irit Yaniv
-
Irit Yaniv，成为公司董事，自2018年5月29日起生效。Rubinstein先生在制药和医疗设备领域拥有多年经验，包括担任Taro Pharmaceuticals Industries首席执行官和总经理20多年，监督该公司被SUN Pharma成功收购。2003年，鲁宾斯坦先生获得了杰出实业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际市场营销课程。鲁宾斯坦先生是MediWound Ltd.、MedisonBiotech、Trima Pharma（他担任董事长）和KSDG的董事会成员。他曾在Exalenz（被VIVO收购）、Kamada（KMDA）和Clal Biotechnology Industries（CBI）的董事会任职，是Sol-Gel Pharma的顾问。鲁宾斯坦还是特拉维夫苏拉斯基医学中心和国家意第绪文化管理局附近的医学研究基金的主任。
Irit Yaniv has been a member of Board since 2023. She has more than 25 years of experience in the venture capital, pharmaceutical and MedTech indtries. As a senior manager, skilled physician, and experienced board member, she possesses a highly developed combination of leadership, decision making and biness skills. Dr. Yaniv has served as partner at Accelmed Ventures since 2012. During this time she led Eximo from pre clinical development through acquisition. Dr. Irit Yaniv previoly served as Executive Director and Chairperson of Accelmed's Innovation Hub portfolio companies, a global group of funds investing and acquiring control in HealthTech companies foced on Buyout and Non Control transactions in commercial stage companies. Dr. Yaniv holds an MD degree from the Ben Gurion University and an MBA from the Recanati Biness School at Tel Aviv University. - Irit Yaniv，成为公司董事，自2018年5月29日起生效。Rubinstein先生在制药和医疗设备领域拥有多年经验，包括担任Taro Pharmaceuticals Industries首席执行官和总经理20多年，监督该公司被SUN Pharma成功收购。2003年，鲁宾斯坦先生获得了杰出实业家奖。在这些年里，他还完成了宾夕法尼亚大学沃顿商学院的国际市场营销课程。鲁宾斯坦先生是MediWound Ltd.、MedisonBiotech、Trima Pharma（他担任董事长）和KSDG的董事会成员。他曾在Exalenz（被VIVO收购）、Kamada（KMDA）和Clal Biotechnology Industries（CBI）的董事会任职，是Sol-Gel Pharma的顾问。鲁宾斯坦还是特拉维夫苏拉斯基医学中心和国家意第绪文化管理局附近的医学研究基金的主任。
- Irit Yaniv has been a member of Board since 2023. She has more than 25 years of experience in the venture capital, pharmaceutical and MedTech indtries. As a senior manager, skilled physician, and experienced board member, she possesses a highly developed combination of leadership, decision making and biness skills. Dr. Yaniv has served as partner at Accelmed Ventures since 2012. During this time she led Eximo from pre clinical development through acquisition. Dr. Irit Yaniv previoly served as Executive Director and Chairperson of Accelmed's Innovation Hub portfolio companies, a global group of funds investing and acquiring control in HealthTech companies foced on Buyout and Non Control transactions in commercial stage companies. Dr. Yaniv holds an MD degree from the Ben Gurion University and an MBA from the Recanati Biness School at Tel Aviv University.
- Christina L. Allgeier
-
Christina L. Allgeier,，于2009年10月起被任命为副总裁兼首席财务官。在此之前，Allgeier女士自2002年12月起担任公司控制人。Allgeier女士毕业于宾夕法尼亚州立大学，获得会计学学士学位。Allgeier女士持有宾夕法尼亚州联邦注册会计师执照。
Christina L. Allgeier was appointed as Vice President and Chief Financial Officer in October 2009. Prior to this time, Ms. Allgeier served as corporate controller since December 2002. Ms. Allgeier graduated with a B.S. in accounting from Penn State University. Ms. Allgeier holds a license from the Commonwealth of Pennsylvania as a certified public accountant. - Christina L. Allgeier,，于2009年10月起被任命为副总裁兼首席财务官。在此之前，Allgeier女士自2002年12月起担任公司控制人。Allgeier女士毕业于宾夕法尼亚州立大学，获得会计学学士学位。Allgeier女士持有宾夕法尼亚州联邦注册会计师执照。
- Christina L. Allgeier was appointed as Vice President and Chief Financial Officer in October 2009. Prior to this time, Ms. Allgeier served as corporate controller since December 2002. Ms. Allgeier graduated with a B.S. in accounting from Penn State University. Ms. Allgeier holds a license from the Commonwealth of Pennsylvania as a certified public accountant.
- Dolev Rafaeli
-
Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel. - Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
- Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel.
高管简历
中英对照 | 中文 | 英文- Shmuel Gov
Shmuel Gov是公司高级副总裁兼总经理，负责公司在加利福尼亚州卡尔斯巴德的制造和研发工厂的运营。他于2015年加入公司，担任副总裁兼总经理。他在医疗器械制造、物流和研发领域拥有超过25年的经验。他拥有电子工程和国际商业管理学位。
Shmuel Gov,is the Company's Senior Vice President and General Manager in charge of operations at the Company's manufacturing and R&D facility in Carlsbad, CA. He joined the Company in 2015 as Vice President and General Manager. He has over 25 years of experience in medical device manufacturing, logistics, and R&D. He holds degrees in electronics engineering and international business management.- Shmuel Gov是公司高级副总裁兼总经理，负责公司在加利福尼亚州卡尔斯巴德的制造和研发工厂的运营。他于2015年加入公司，担任副总裁兼总经理。他在医疗器械制造、物流和研发领域拥有超过25年的经验。他拥有电子工程和国际商业管理学位。
- Shmuel Gov,is the Company's Senior Vice President and General Manager in charge of operations at the Company's manufacturing and R&D facility in Carlsbad, CA. He joined the Company in 2015 as Vice President and General Manager. He has over 25 years of experience in medical device manufacturing, logistics, and R&D. He holds degrees in electronics engineering and international business management.
- John Gillings
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Dolev Rafaeli
Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel.- Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
- Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel.